Identification of novel therapies for genetically defined CLL cases through repurposing of already approved drugs
Školitel: Mgr. Michal Šmída, Ph.D.
Instituce: Masaryk University, Faculty of Science
O mém projektu
Chronic lymphocytic leukaemia (CLL) is a heterogenic disease with limited therapeutic options. Novel possibilities in the treatment are urgently needed, designed for each specific genetic background of patients with CLL disease. Such personalized therapy can be provided by therapeutic switching, or also called drug repurposing. For this scientific approach, a library of biologically active compounds is chosen to dissect novel potential targets of therapy for the most relevant genetic subgroups of CLL patients. These compounds will be applied on both primary cells and immortalized cell lines edited by CRISPR/Cas9 system, cultured in established co-culture model of cultivation mimicking the tumour microenvironment. The research project also offers a detailed elucidation of the underlying molecular mechanisms with a great potential for an efficient stratified therapy.